Incyte stock maintains strong momentum, trading above key moving averages after reporting robust Q2 growth and lifting its long-term revenue outlook.
Incyte raised FY2026 sales guidance and reported strong Q2 sales growth, with the stock outperforming the biotech ETF over recent months.
Exelixis was highlighted as a comparable biotech peer with strong 52-week and YTD gains of 46.9% and 32.7% respectively.
The SPDR S&P Biotech ETF was used as the sector benchmark, showing gains of 11% over three months and 32.8% YTD.
Incyte Corporation shares have surged 22.5% over the last three months, fueled by a 40.5% year-over-year jump in Q2 revenue to $1.5 billion. Management has raised its FY2026 sales guidance to a range of $5.13 billion to $5.26 billion as the company diversifies its oncology and hematology portfolio ahead of the 2028 patent expiry for its flagship drug, Jakafi.
Incyte is expanding its pipeline beyond its flagship drug, Jakafi, to mitigate revenue risks associated with the drug's expected patent expiration in 2028.